Who Needs Negotiation? US Rx Prices Are Falling – Thanks To Generics
Executive Summary
A Congressional Budget Office review of prescription drug pricing trends over the past decade shows a surprising fact: the average costs per prescription in the US is falling. That probably won’t change the political debate over drug prices – but maybe it should.
You may also be interested in...
Medicare Drug Price Negotiation Not A Major Threat To Pharma – Even If It Passes
Biopharma analysts discuss the likely impact of the drug pricing reform provisions in the Build Back Better legislation, which has hit a roadblock created by Democratic Senator Joe Manchin of West Virginia.
End Of ‘Phase I’: The Case To Re-Name First-In-Human Oncology Trials
US FDA’s push to re-think oncology dosing should begin by renaming the initial human trials to de-emphasize toxicity, a National Cancer Institute official suggests.
Slow Down To Speed Up: US FDA Presses Cases For Dose Optimization
The US FDA is urging drug companies to abandon traditional approaches to oncology dosing even if it means slowing down early studies. The trade-off should be faster development times overall, FDA says – but sponsors still seem very wary.